We and our partners use cookies and other tracking technologies to collect data relating to you to perform analytics, improve your experience of using our website, provide you with personalized ads and content based on your interactions with these and other websites and allow you to share content on social media. By clicking “Accept All Cookies”, you consent to this and to the sharing of this data with our partners. You can change your consent preferences at any time in the “Cookie Settings” section at the bottom of our website. Review our Cookie Notice to learn more about our practices.
What research is being done on molecule-based biologic agents?

Proteins, ligands, nucleic acids, neurotransmitters, enzymes, and other molecules are integral to cellular communication and drive cellular mechanisms, and are thus critical to physiological and pathological function alike. Molecular biologics can be used to directly affect cell phenotypes and behaviors (i.e., cytokines, exosomes), promote targeted cell-cell interactions (e.g., antibodies), or facilitate the targeted delivery of another agent (i.e., viral vectors, nanoparticles).
While tissue-based agents can be constructed using extracted cells and cell-based agents can be developed by modulating existing cells, the production of molecule-based biologics generally requires the creation of a “cellular factory” – a cell which has been engineered to produce and/or secrete the desired agent in question. Much research has been dedicated to identifying the best “factory” cells, optimizing production yield and efficiency, and minimizing final product variability from a structural and conformational standpoint, with the aim of ensuring that a constant and stable supply of molecule-based biologics is available for basic, translational, and clinical scientific demands.